Risperidone Cross-over design query [Design Issues]

posted by Rahul  – India, 2008-12-24 07:11 (6389 d 11:38 ago) – Posting: # 2968
Views: 6,810

Dear members,

I am working on Risperidone 1 mg orally desintegrating tablet.

The lable claim indicate:-
1. Tmax: Risperidone- 1 hr.
9-OH Risperidone- 3 hrs. in Extensive metabolizers & 17 hrs. in poor metabolizers.

2. Apperent T1/2: Risperidone- 3 hrs. in Extensive metabolizers & 20 hrs. in poor metabolizers.
9-OH Risperidone- 21 hrs. in Extensive metabolizers & 30 hrs. in poor metabolizers.

3. Steady State conc.: Risperidone- 1 day in Extensive metabolizers & 5 days in poor metabolizers.
9-OH Risperidone- 5-6 days in Extensive metabolizers

So, I want to ask that, while designing protocol for 2-way cross-over study, what in the significance of Extensive & poor metabolizers?

For calculating total sampling Hrs. and wash-out period, is it nessary to consider poor metabilizers effect?

So kindly guide me regarding the same...

Thanks n Regards,
Rahul...

Thanks n regards,
Rahul...

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,571 registered users;
146 visitors (0 registered, 146 guests [including 31 identified bots]).
Forum time: 19:50 CEST (Europe/Vienna)

Scientists cannot simply hang their subjectivities
up on a hook outside the laboratory door.    Ruth Bleier

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5